Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells attack many tumour cell lines, and are thought to have a critical role in anti-tumour immunity; however, the interaction between NK cells and tumour targets is poorly understood. The stimulatory lectin-like NKG2D receptor is expressed by NK cells, activated CD8+ T cells and by activated macrophages in mice. Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identified, some of which are expressed at high levels by tumour cells but not by normal cells in adults. However, no direct evidence links the expression of these 'induced self' ligands with tumour cell rejection. Here we demonstrate that ectopic expression of the murine NKG2D ligands Rae1beta or H60 in several tumour cell lines results in potent rejection of the tumour cells by syngeneic mice. Rejection is mediated by NK cells and/or CD8+ T cells. The ligand-expressing tumour cells induce potent priming of cytotoxic T cells and sensitization of NK cells in vivo. Mice that are exposed to live or irradiated tumour cells expressing Rae1 or H60 are specifically immune to subsequent challenge with tumour cells that lack NKG2D ligands, suggesting application of the ligands in the design of tumour vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“NKG2D has been implicated in immune surveillance of tumors using transgenic models of spontaneous cancer as well as subcutaneous tumor transfer models (Cerwenka et al., 2001; Diefenbach et al., 2001; Guerra et al., 2008).”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
In the citing paper
“Previous studies from our laboratory demonstrated that transplanted tumor cells expressing NKG2D ligands are rejected by NK cells and, in some cases, T cells (Diefenbach et al., 2000, 2001, 2003)”
From p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells (2013) · cites this paper as Diefenbach et al., 2001
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Biology of Natural Killer Cells
Trinchieri, G. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60664-1 · Cited by 2,902
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818 · cited 1×
“However, this was not the case with irradiated ligand-negative B16-BL6 tumour cell”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Counting Antigen-Specific CD8 T Cells: A Reevaluation of Bystander Activation during Viral Infection
Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J. D., Zajac, A. J., Miller, J. D., Slansky, J., & Ahmed, R. (1998) · Immunity · doi:10.1016/s1074-7613(00)80470-7 · Cited by 1,943 · cited 1×
“IFN-γ production was assayed by stimulating CTLs or NK cells with an equal number of target cells for 5–7 h and staining intracellular IFN-γ as describe”
MethodActivating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778 · cited 1×
“It is unknown whether engagement of NKG2D in NK cells results in direct stimulation or supplies a co-stimulatory signal that acts in conjunction with signals from other stimulatory receptor”
BackgroundDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Cosman, D., Müllberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, M., & Chalupny, N. J. (2001) · Immunity · doi:10.1016/s1074-7613(01)00095-4 · Cited by 1,232 · cited 1×
“Several distinct cell-surface ligands that are related to class I major histocompatibility complex molecules have been identifie”
BackgroundRole of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Lanier, L. L. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,769
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
“Besides NKG2D, NK cells have a repertoire of different stimulatory cell surface receptors, which, upon binding to their tumor-derived ligands, activate NK cells (Cerwenka et al. 2000; Diefenbach et al. 2000, 2001; Raulet 2003).”
BackgroundBöttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
“Cells undergoing neoplastic transformation often show increased expression of ligands for NK cell activating receptors (Diefenbach et al., 2001; Gasser et al., 2005), which endow NK cells with the ability to participate in tissue stress surveillance responses (Hayday, 2009; Raulet and Guerra, 2009).”
BackgroundTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Roles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
Self-citationNK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
“Decades of research in rodents have demonstrated the importance of NK cells in tumor clearance (14, 117, 247, 248).”
BackgroundNatural selection of tumor variants in the generation of “tumor escape” phenotypes
Khong, H. T., & Restifo, N. P. (2002) · Nature Immunology · doi:10.1038/ni1102-999 · Cited by 1,058
Targeting neoantigens to augment antitumour immunity
Yarchoan, M., Johnson, B. A., Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.154 · Cited by 997
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Self-citationSmyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850
“Transfected tumor cell lines expressing NKG2D ligands are rejected in vivo in an NKG2D-dependent fashion (Cerwenka et al., 2001; Diefenbach et al., 2001).”
BackgroundSelf-citationRegulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
“In conventional CD8+ T cells, NKG2D may also provide costimulatory function (16, 17), although this is most evident for the subset of highly activated CD8+ T cells that lacks expression of CD28, the conventional costimulatory receptor for T cells (16).”
BackgroundSelf-citationDoes the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
New aspects of natural-killer-cell surveillance and therapy of cancer
Smyth, M. J., Hayakawa, Y., Takeda, K., & Yagita, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc928 · Cited by 752
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Activation of NK cell cytotoxicity
Smyth, M. J., Cretney, E., Kelly, J. M., Westwood, J. A., Street, S. E. A., Yagita, H., Takeda, K., Dommelen, S. L. H. V., Degli-Esposti, M. A., & Hayakawa, Y. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.07.034 · Cited by 714
Neutrophil-derived cytokines: facts beyond expression
Tecchio, C., Micheletti, A., & Cassatella, M. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00508 · Cited by 699
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
“In vivo experiments assessing a functional role of NKG2DL for tumour surveillance demonstrated that ectopic expression of Rae1b and H60 conferred a strong immunostimulatory capacity to otherwise tumour-forming malignant cell lines (Cerwenka et al., 2001; Diefenbach et al., 2001).”
BackgroundResultA Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
de Pillis, L. G., Radunskaya, A. E., & Wiseman, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0564 · Cited by 649
“Assumption (2) is reflected in the cell-cell kill term; assumption (3) gives rise to the effector cell recruitment terms; and assumption ( 6 ) is incorporated through the effector inactivation terms.”
BackgroundMethodInfluentialThe Role of the NKG2D Immunoreceptor in Immune Cell Activation and Natural Killing
Jamieson, A. M., Diefenbach, A., McMahon, C. W., Xiong, N., Carlyle, J. R., & Raulet, D. H. (2002) · Immunity · doi:10.1016/s1074-7613(02)00333-3 · Cited by 647
“(Bauer et al., 1999; Cerwenka et al., 2000; Diefenbach et al., 2000, 2001).”
Self-citationCutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
“Furthermore, in mice RAE-1-transduced cell lines were eliminated in vivo due to NK and CD8 T cell activity and induced tumor immunity against the parental cell line, supporting a role for NKG2D in the tumor immune surveillance (16, 17).”
BackgroundMarcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 611
“, double-stranded RNA), and vaccination with irradiated tumor cells (Chaix et al., 2008; Diefenbach et al., 2001; Glas et al., 2000; Guia et al., 2008; Mortier et al., 2009).”
Self-citationNKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599
“Studies using transplantable mouse tumors have demonstrated that expression of an NKG2D ligand is sufficient to cause rejection of the tumor (62, 63).”
BackgroundFernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S., & Raulet, D. H. (2005) · Blood · doi:10.1182/blood-2004-08-3156 · Cited by 588
Self-citationRoles of natural killer cells in immunity to cancer, and applications to immunotherapy
Wolf, N. K., Kissiov, D. U., & Raulet, D. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00732-1 · Cited by 577
Self-citationde Pillis, L. G., Gu, W., & Radunskaya, A. E. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2005.06.037 · Cited by 575
“Both NK and CD8 þ T cells are capable of killing tumor cells (see, for example, Diefenbach et al., 2001; Kawarada et al., 2001; Germain, 2004).”
InfluentialImmune functions encoded by the natural killer gene complex
Yokoyama, W. M., & Plougastel, B. F. M. (2003) · Nature Reviews Immunology · doi:10.1038/nri1055 · Cited by 565
Activating and inhibitory receptors of natural killer cells
Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.78 · Cited by 555
Close encounters of different kinds: Dendritic cells and NK cells take centre stage
Degli-Esposti, M. A., & Smyth, M. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1549 · Cited by 554
γδ T cells for immune therapy of patients with lymphoid malignancies
Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weissinger, F., Ruediger, T., & Tony, H.-P. (2003) · Blood · doi:10.1182/blood-2002-12-3665 · Cited by 550
“1 106 4 62 (3-153) 45 (0-122) 0/4 (0) 23 (18-27) 8 ( 38-54) 0/2 (0) 183 (82-426) 322 (0-1253) 3/4 (75) 2 106 3 65 (52-98) 60 (19-121) 2/3 (66) 81 ( 37-103) 93 (79-291) 2/3 (66) 186 (62-230) 124 (122-571) 3/3 (100)”
InfluentialLee, J.-C., Lee, K.-M., Kim, D.-W., & Heo, D. S. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7335 · Cited by 549
“Indeed, tumor cells expressing Rae1 or H60 were shown to be efficiently lysed in vitro and completely rejected by syngeneic mice (12, 13).”
BackgroundFunctional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Salih, H. R., Antropius, H., Gieseke, F., Lutz, S. Z., Kanz, L., Rammensee, H.-G., & Steinle, A. (2003) · Blood · doi:10.1182/blood-2003-01-0019 · Cited by 541
Regulation of immune cell function and differentiation by the NKG2D receptor
Zafirova, B., Wensveen, F. M., Gulin, M., & Polić, B. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0797-0 · Cited by 538
“Early experiments showed that overexpression of NKG2D ligands in cancer cells caused tumor rejection after transplantation in mice [74, 75].”
Rubinstein, N., Alvarez, M., Zwirner, N. W., Toscano, M. A., Ilarregui, J. M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O. L., & Rabinovich, G. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00024-8 · Cited by 531
“…factor in the development of antitumor immunity following different stimuli, includingnation of in vitro and in vivo experiments using knockdown transfectants, we established a link between Gal-1-mediated overexpression of CD70 (Kelly et al., 2002) or NKG2D ligands (Diefenbach et al., 2001).”
BackgroundThe NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies
Bald, T., Krummel, M. F., Smyth, M. J., & Barry, K. C. (2020) · Nature Immunology · doi:10.1038/s41590-020-0728-z · Cited by 506
Pende, D., Rivera, P., Marcenaro, S., Chang, C., Biassoni, R., Conte, R., Kubin, M. Z., Cosman, D. J., Ferrone, S., Moretta, L., et al. (2002) · PubMed · Cited by 593
Dieli, F., Vermijlen, D., Fulfaro, F., Caccamo, N., Meraviglia, S., Cicero, G., Roberts, A., Buccheri, S., D'Asaro, M., Gebbia, N., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0199 · Cited by 497
“... cells are indeed infiltrating the tumors and/or are helping other cells to do so. Wang and colleagues recently reported that human prostate and breast carcinoma are naturally and strongly infiltrated by TRAIL-producing gy T cells,7 suggesting the value of analyzing the regulation on zoledronate + IL-2–stimulated-V…”
Effect of NKG2D ligand expression on host immune responses
Champsaur, M., & Lanier, L. L. (2010) · Immunological Reviews · doi:10.1111/j.0105-2896.2010.00893.x · Cited by 488
“Ectopic expression of NKG2D ligands on tumors renders them susceptible to NK cell lysis in vitro (68, 69).”
BackgroundOppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., & Hayday, A. C. (2005) · Nature Immunology · doi:10.1038/ni1239 · Cited by 454
Diefenbach, A., Tomasello, E., Lucas, M., Jamieson, A. M., Hsia, J. K., Vivier, E., & Raulet, D. H. (2002) · Nature Immunology · doi:10.1038/ni858 · Cited by 452
Self-citationHsu, K. C., Chida, S., Geraghty, D. E., & Dupont, B. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.19004.x · Cited by 443
Natural Killer Cell Education and Tolerance
Orr, M. T., & Lanier, L. L. (2010) · Cell · doi:10.1016/j.cell.2010.08.031 · Cited by 441
“Immunocompetent adult mice reject transplanted tumors expressing NKG2D ligands and eliminate virus-infected cells in which NKG2D ligands are induced (Cerwenka et al., 2001; Champsaur and Lanier, 2010; Diefenbach et al., 2001; Lodoen et al., 2003, 2004).”
Natural Killer Cells and Cancer
(2003) · Advances in Cancer Research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 438
Viaud, S., Terme, M., Flament, C., Taieb, J., André, F., Novault, S., Escudier, B., Robert, C., Caillat-Zucman, S., Tursz, T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004942 · Cited by 437
“were not present in the initial vaccine [28,29], suggesting that alternate effectors elicited by the vaccine could mediate tumor destruction and subsequent CTL responses [30].”
BackgroundNKG2D recruits two distinct adapters to trigger NK cell activation and costimulation
Gilfillan, S., Ho, E. L., Cella, M., Yokoyama, W. M., & Colonna, M. (2002) · Nature Immunology · doi:10.1038/ni857 · Cited by 437
Interactions Between the Immune System and Cancer: A Brief Review of Non-spatial Mathematical Models
Eftimie, R., Bramson, J. L., & Earn, D. J. D. (2011) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9526-3 · Cited by 435
“Fitting the model to data from Diefenbach et al. (2001), the authors discovered that lysis of tumor cells by effector cells can be better explained if one associates different mechanisms (i.e., different types of interaction terms) with cancer elimination by NK cells and by CD8+ T cells.”
MethodMocikat, R., Braumüller, H., Gumy, A., Egeter, O., Ziegler, H., Reusch, U., Bubeck, A., Louis, J., Mailhammer, R., Riethmüller, G., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00264-4 · Cited by 433
“This threshold may explain why noncytopathic(Diefenbach et al. 2001; Hayakawa et al., 2002).”
BackgroundInfluentialCD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
“Accumulating evidence suggests that im munemediated destruction of senescent cells”
Self-citationInterplay of natural killer cells and their receptors with the adaptive immune response
Raulet, D. H. (2004) · Nature Immunology · doi:10.1038/ni1114 · Cited by 413
Self-citationNKG2D ligands in tumor immunity
Nausch, N., & Cerwenka, A. (2008) · Oncogene · doi:10.1038/onc.2008.272 · Cited by 408
“It was observed that tumor cells expressing high levels of NKG2D ligands were efficiently rejected by NK cells, whereas tumor cells expressing intermediate levels of NKG2D ligands were less immunogenic (Diefenbach et al., 2001).”
Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H., & Wang, R.-F. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.020 · Cited by 408
A novel dendritic cell subset involved in tumor immunosurveillance
Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., Péquignot, M., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 405
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature Reviews Immunology · doi:10.1038/nri2604 · Cited by 404
Self-citationRecognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
“is crucial for tumor cell elimination both in vitro and in tumor transplantation experiments in vivo (Bauer et al., 1999; Cerwenka, Baron, & Lanier, 2001; Diefenbach et al., 2001).”
Self-citationRole of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
Verneris, M. R., Karami, M., Baker, J., Jayaswal, A., & Negrin, R. S. (2004) · Blood · doi:10.1182/blood-2003-06-2125 · Cited by 383
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 381
“For example, many transplanted tumor cells are rejected in an NK cell-dependent manner [146].”
BackgroundNatural Killer Cell Accumulation in Tumors Is Dependent on IFN-γ and CXCR3 Ligands
Wendel, M., Galani, I. E., Suri-Payer, E., & Cerwenka, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1440 · Cited by 378
“In concordance with previous reports (13, 22), we observed that lower numbers of NK cells accumulated in RMA tumors compared with RMA-S tumors (Figs.”
InfluentialDisulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Kaiser, B. K., Yim, D., Chow, I.-T., Gonzalez, S., Dai, Z., Mann, H. H., Strong, R. K., Groh, V., & Spies, T. (2007) · Nature · doi:10.1038/nature05768 · Cited by 377
Tumor-Associated MICA Is Shed by ADAM Proteases
Waldhauer, I., Goehlsdorf, D., Gieseke, F., Weinschenk, T., Wittenbrink, M., Ludwig, A., Stevanovic, S., Rammensee, H.-G., & Steinle, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6768 · Cited by 375
Promiscuity and the single receptor: NKG2D
Eagle, R. A., & Trowsdale, J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2144 · Cited by 374
Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A., Böll, B., Simhadri, V. L., Borchmann, P., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.010 · Cited by 374
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
“In previous studies, the observed NKG2D-mediated activation of cytotoxic lymphocytes was critically dependent on NKG2DL expression levels at the cell surface (31, 32).”
Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection
Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., & Smyth, M. J. (2002) · Nature Immunology · doi:10.1038/ni746 · Cited by 356
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 342
“Immune depletion and other experiments showed that rejection was dependent on NK cells and/or CD8 T cells and perforin (22, 23).”
BackgroundInfluentialNatarajan, K., Dimasi, N., Wang, J., Mariuzza, R. A., & Margulies, D. H. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064812 · Cited by 335
Carbone, E. (2005) · Blood · doi:10.1182/blood-2004-04-1422 · Cited by 333
Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., & Plymate, S. R. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422206 · Cited by 330
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
Doubrovina, E. S., Doubrovin, M. M., Vider, E., Sisson, R. B., O’Reilly, R. J., Dupont, B., & Vyas, Y. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6891 · Cited by 324
“We hypothesize that production of MMPs in the tumor microenvironment leads to proteolytic cleavage and release of NKG2DLs, particularly MIC molecules.”
BackgroundResultInfluentialHuman microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D
Stern-Ginossar, N., Gur, C., Biton, M., Horwitz, E., Elboim, M., Stanietsky, N., Mandelboim, M., & Mandelboim, O. (2008) · Nature Immunology · doi:10.1038/ni.1642 · Cited by 315
Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction
Cao, W., Bover, L., Cho, M., Wen, X., Hanabuchi, S., Bao, M., Rosen, D. B., Wang, Y.-H., Shaw, J. L., Du, Q., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090547 · Cited by 313
“…et al., 2005), and NKG2D interacts with ligands with structural homology with MHC class I, including RAE-1-, H60, and MULT1 (Cerwenka et al., 2000; Diefenbach et al., 2001, 2003; Carayannopoulos et al., 2002), expression of which is under control of TLR activation, viral infections, and stress…”
BackgroundActivation of Vγ9Vδ2 T Cells by NKG2D
Rincon-Orozco, B., Kunzmann, V., Wrobel, P., Kabelitz, D., Steinle, A., & Herrmann, T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2144 · Cited by 313
“NKG2D in tumor control has been obtained for NK cells and CD8 T cells in mouse lymphoma models (25) and for T cells in a mouse model of skin tumor development (26).”
BackgroundImmunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
IL-21 Induces the Functional Maturation of Murine NK Cells
Brady, J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2048 · Cited by 303
“Rae-1 is one of a family of inducible ligands for the activating receptor NKG2D that represents one of the initial mechanisms for detecting abnormal or stressed cells in vivo (34).”
BackgroundBorg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302
NK Cell Compartments and Their Activation by Dendritic Cells
Ferlazzo, G., & Münz, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.3.1333 · Cited by 299
“In addition, mice that have been challenged with ligand-expressing tumors develop T cell immunity against parental tumor cells not expressing NKG2D ligands (72).”
BackgroundNatural killer cell-mediated immunosurveillance of human cancer
Malmberg, K.-J., Carlsten, M., Björklund, A., Sohlberg, E., Bryceson, Y. T., & Ljunggren, H.-G. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.002 · Cited by 299
The immune system in cancer metastasis: friend or foe?
Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D., & Overwijk, W. W. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0283-9 · Cited by 292
“In xenograft models of cancer cell lines, expression of NKG2D ligands resulted in tumor rejection [61, 62] and an antibody blocking NKG2D increased the growth of methylcholanthrene (MCA)-induced fibrosarcoma [63].”
BackgroundLundholm, M., Schröder, M., Nagaeva, O., Baranov, V., Widmark, A., Mincheva-Nilsson, L., & Wikström, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108925 · Cited by 291
“Earlier studies have shown that various tumor cells express high levels of NKG2D ligands that after transplantation in mice caused an NKG2D-dependent tumor rejection [32,33].”
BackgroundNatural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
Andoniou, C. E., van Dommelen, S. L. H., Voigt, V., Andrews, D. M., Brizard, G., Asselin-Paturel, C., Delale, T., Stacey, K. J., Trinchieri, G., & Degli-Esposti, M. A. (2005) · Nature Immunology · doi:10.1038/ni1244 · Cited by 285
Sutherland, C. L., Chalupny, N. J., Schooley, K., VandenBos, T., Kubin, M., & Cosman, D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.671 · Cited by 276
“Murine ligands for NKG2D, the RAE-1 and H-60 proteins, are induced on some tumors (35, 36), and their ectopic expression on tumor cell lines mediates potent rejection of MHC class I-bearing tumors in vivo (37, 38).”
BackgroundLodoen, M., Ogasawara, K., Hamerman, J. A., Arase, H., Houchins, J. P., Mocarski, E. S., & Lanier, L. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021973 · Cited by 275
“Similarly, recent studies have shown that NK cells are capable of rejecting tumors bearing MHC class I if they express NKG2D ligands (13, 14).”
BackgroundResultGhiringhelli, F., Ménard, C., Martin, F., & Zitvogel, L. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00445.x · Cited by 273
“Conversely, ectopic expression of Rae1, a mouse NKG2D ligand, promotes NK-cell-mediated rejection of tumors (22, 23).”
BackgroundBorrego, F., Kabat, J., Kim, D.-K., Lieto, L., Maasho, K., Peña, J., Solana, R., & Coligan, J. E. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(01)00107-9 · Cited by 271
Dendritic and Natural Killer Cells Cooperate in the Control/Switch of Innate Immunity
Zitvogel, L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012040 · Cited by 268
“The relevance of innate effectors such as NK cells in resistance to herpes viridae‐related infections (9) and tumors ( 10 ) is being established.”
BackgroundKIR2DL4 (CD158d), an NK Cell-Activating Receptor with Inhibitory Potential
Faure, M., & Long, E. O. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.12.6208 · Cited by 268
The promise of cancer vaccines
Gilboa, E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1359 · Cited by 267
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264
“In the past 5 yr we have begun to appreciate the activation receptors expressed by innate effector cells, such as NK cells and TCR T cells (28, 34).”
BackgroundResultSelf-citationDoes the Immune System Naturally Protect Against Cancer?
Corthay, A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00197 · Cited by 261
“The importance of NKG2D for cancer immunosurveillance in vivo gained support from experiments showing that cancer cells transfected with NKG2D ligands and injected into mice were rapidly rejected by NK cells and by CD8 T cells (91, 92).”
BackgroundSkov, S., Pedersen, M. T., Andresen, L., Thor Straten, P., Woetmann, A., & Ødum, N. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0599 · Cited by 259
“Diefenbach et al. ( 23 ) have shown that RAE-1-transfected cancer cells can be eliminated in vivo by NK cell and CD8 T-cell activities, which also induced adaptive immunity to the parental tumor cells without RAE-1 expression.”
BackgroundIlander, M., Olsson-Strömberg, U., Schlums, H., Guilhot, J., Brück, O., Lähteenmäki, H., Kasanen, T., Koskenvesa, P., Söderlund, S., Höglund, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.360 · Cited by 250
Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., & Dranoff, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711293105 · Cited by 256
Metadata
- Authors
- Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H.
- Affiliations
- University of California, Berkeley (US)
- Corresponding author
- Raulet, David H.
- Venue
- Nature
- Published
- 2001-09-13
- Volume
- 413
- Issue
- 6852
- Pages
- 165-171
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3900321
- OpenAlex
- W1595098530
- Cited by
- 1,083
- References
- 30
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 26 · 2023: 38 · 2022: 28 · 2021: 43 · 2020: 48 · 2019: 37 · 2018: 38 · 2017: 32 · 2016: 34 · 2015: 53 · 2014: 42 · 2013: 48 · 2012: 42
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI039642)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- NKG2D, Rae1, NKG2D ligands, natural killer cells, tumour immunity, tumor rejection, CD8+ T cells, cancer vaccines, MHC class I
- MeSH terms
- Animals, Cytotoxicity, Immunologic, Immunity, Killer Cells, Natural, Ligands, Membrane Proteins, Mice, Inbred C57BL, Neoplasms, Receptors, Immunologic, Recombinant Proteins, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Minor Histocompatibility Antigens, CD8-Positive T-Lymphocytes, Mice, Receptors, Natural Killer Cell, NK Cell Lectin-Like Receptor Subfamily K
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.